IL325482A - Crystalline forms of 6-(6-(((1r,2r,3s,5s)-2-fluoro-9-azabicyclo[3.3.1]nonan-3-yl)(methyl)amino)pyridazin-3-yl)-2-methylbenzo[d]oxazol-5-ol, a splicing modulator for the treatment of huntington's disease - Google Patents

Crystalline forms of 6-(6-(((1r,2r,3s,5s)-2-fluoro-9-azabicyclo[3.3.1]nonan-3-yl)(methyl)amino)pyridazin-3-yl)-2-methylbenzo[d]oxazol-5-ol, a splicing modulator for the treatment of huntington's disease

Info

Publication number
IL325482A
IL325482A IL325482A IL32548225A IL325482A IL 325482 A IL325482 A IL 325482A IL 325482 A IL325482 A IL 325482A IL 32548225 A IL32548225 A IL 32548225A IL 325482 A IL325482 A IL 325482A
Authority
IL
Israel
Prior art keywords
methylbenzo
nonan
pyridazin
oxazol
azabicyclo
Prior art date
Application number
IL325482A
Other languages
Hebrew (he)
Original Assignee
Skyhawk Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Skyhawk Therapeutics Inc filed Critical Skyhawk Therapeutics Inc
Publication of IL325482A publication Critical patent/IL325482A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
IL325482A 2023-06-30 2025-12-21 Crystalline forms of 6-(6-(((1r,2r,3s,5s)-2-fluoro-9-azabicyclo[3.3.1]nonan-3-yl)(methyl)amino)pyridazin-3-yl)-2-methylbenzo[d]oxazol-5-ol, a splicing modulator for the treatment of huntington's disease IL325482A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363511325P 2023-06-30 2023-06-30
PCT/US2024/036019 WO2025006887A1 (en) 2023-06-30 2024-06-28 Crystalline forms of 6-(6-(((1r,2r,3s,5s)-2-fluoro-9-azabicyclo[3.3.1]nonan-3-yl)(methyl)amino)pyridazin-3-yl)-2-methylbenzo[d]oxazol-5-ol, a splicing modulator for the treatment of huntington's disease

Publications (1)

Publication Number Publication Date
IL325482A true IL325482A (en) 2026-02-01

Family

ID=91966897

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325482A IL325482A (en) 2023-06-30 2025-12-21 Crystalline forms of 6-(6-(((1r,2r,3s,5s)-2-fluoro-9-azabicyclo[3.3.1]nonan-3-yl)(methyl)amino)pyridazin-3-yl)-2-methylbenzo[d]oxazol-5-ol, a splicing modulator for the treatment of huntington's disease

Country Status (7)

Country Link
EP (1) EP4735437A1 (en)
KR (1) KR20260044269A (en)
CN (1) CN121752562A (en)
AR (1) AR133116A1 (en)
AU (1) AU2024307361A1 (en)
IL (1) IL325482A (en)
WO (1) WO2025006887A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114126613A (en) 2019-02-05 2022-03-01 斯基霍克疗法公司 Methods and compositions for modulating splicing

Also Published As

Publication number Publication date
KR20260044269A (en) 2026-04-01
AR133116A1 (en) 2025-08-27
CN121752562A (en) 2026-03-27
AU2024307361A1 (en) 2026-01-22
EP4735437A1 (en) 2026-05-06
WO2025006887A1 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
IL325481A (en) 6-(6-(((1 r,2r,3s,5s)-2-fluoro-9-azabicyclo[3.3.1]nonan-3-yl)(methyl)amino)pyrida zin-3- yl)-2- methylbenzo[d]oxazol-5-ol as a splicing modulator for the treatment of neurological diseases
NO993281L (en) Thin, comfortable interlabial absorbent structure
DE69716905D1 (en) ANALOGS OF THE GLUCAGON-LIKE PEPTIDES -2
PL378030A1 (en) Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
WO2021079196A3 (en) Mettl3 modulators
PH12022550182A1 (en) Selective estrogen receptor degrader
IL325482A (en) Crystalline forms of 6-(6-(((1r,2r,3s,5s)-2-fluoro-9-azabicyclo[3.3.1]nonan-3-yl)(methyl)amino)pyridazin-3-yl)-2-methylbenzo[d]oxazol-5-ol, a splicing modulator for the treatment of huntington&#39;s disease
DK0966277T3 (en) Use of R-NSAIDs to prevent Alzheimer&#39;s disease
CA3296575A1 (en) Crystalline forms of 6-(6-(((1r,2r,3s,5s)-2-fluoro-9-azabicyclo[3.3.1]nonan-3-yl)(methyl)amino)pyridazin-3-yl)-2-methylbenzo[d]oxazol-5-ol, a splicing modulator for the treatment of huntington&#39;s disease
NO20014241D0 (en) C16-unsaturated FP-selective prostaglandin analogs
AU3692997A (en) Veterinary use of a pleuromutilin derivative
PH12022550254A1 (en) MICROMOLECULE PI4KIIIa INHIBITOR COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF
CA3296747A1 (en) 6-(6-(((1 r,2r,3s,5s)-2-fluoro-9-azabicyclo[3.3.1]nonan-3-yl)(methyl)amino)pyrida zin-3- yl)-2- methylbenzo[d]oxazol-5-ol as a splicing modulator for the treatment of neurological diseases
EA200000411A2 (en) High purity (1r,2r,4r)-(-)-2-[n,n-(dimethyllaminoethoxy)]-2-phenyl-1,7,7-trimethyl-bicyclo[2.2.1]heptane, pharmaceutical acceptable salts thereof, process for preparing the same and medicaments containg one or more of said compounds
AU2020326552A8 (en) Pyrimidine-5-carboxamide compound
ZA202400679B (en) Dimethyl-substituted thiazololactam compound and use thereof
CA3275424A1 (en) Trehalose for treating huntington&#39;s disease
CA3277651A1 (en) Pridopidine for treating juvenile huntington&#39;s disease
HK40084817A (en) Compounds for treating huntington&#39;s disease
ATE245982T1 (en) USE OF 2-AMINO-6-TRIFLUOROMETHOXYBENZOTHIAZOLE FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE PREVENTION OR TREATMENT OF CEREBELLUM DISEASES
EP4045671A4 (en) Process of preparing (1r, 4r, 5s)-4-(2-chloroethyl)-1-((s)-((s)-cyclohex-2-en-1-yl)(hydroxy)methyl)-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione(salinosporamide a; marizomib)
CA3273506A1 (en) A composition for treating parkinson&#39;s disease
PL367628A1 (en) Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia
EP4317434A4 (en) Rna delivery system for treatment of huntington&#39;s disease
WO2000076490A3 (en) Methods and compositions for treating urinary frequency and urgency using optically pure (s)-oxybutynin